Figure 3. Vactosertib improves survival and inhibits human OS tumor growth in vivo.

A) NSG mice were inoculated with 1×10⁶ human SAOS2 hOS cells (s.c.) and were treated with Vactosertib (50 mg/kg, p.o. 5 days/week), starting on day 67 after tumor injection. B) Survival rate (n=5). C) tumor sizes were measured by caliper. N=5/each group, ***p<0.001 a two-way ANOVA between groups followed by post-hoc Bonferroni’s multiple comparison tests. D) Representative tumor pictures, E) p-Smad2, β-actin expressions in tumors, F) mRNA expressions of c-Myc in vehicle or Vactosertib treated groups. N=5, **p<0.01 using an unpaired, two-tailed t-test. G) Experimental design. BALB/c mice were inoculated with 1×10⁶ K7M2 (s.c.) on Day 0, and then treated with vehicle (p.o) or Vactosertib (50 mg/kg, p.o. 5 days/week) starting on day 11. H) tumor sizes were measured by caliper. N=4, ***p<0.001 using a two-way ANOVA between groups followed by post-hoc Bonferroni’s multiple comparison tests.